Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ARSUF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ARSUF and 80,000+ other tickers.
See exactly how ARSUF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ARSUF and 80,000+ other tickers.
Fagron N.V. is a specialized pharmaceutical compounding firm focused on delivering tailored medicinal solutions. The company caters to a diverse range of clients, including hospitals, pharmacies, clinics, and individual patients. Beyond providing direct services, Fagron N.V. actively drives innovation by developing cutting-edge concepts, delivery methods, and specific formulations for pharmaceutical compounding. Its extensive product line includes essential raw materials, specialized tools and equipment, semi-finished goods, various drug vehicles, and both sterile and non-sterile…
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 May 2026 – 6PM CET Fagron shareholders approve all proposed resolutions at the General Meetings Fagron, the leading global player in pharmaceutical compounding, today held its Annual and Extraordinary General Meeting of Shareholders. All resolutions proposed by the Board of Directors were approved.
Fagron NV (ARSUF) Q1 2026 Sales/Trading Call Transcript
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2026 – 7 AM CEST Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026 Fagron NV invites its shareholders and holders of subscription rights to attend its Ordinary General Meeting and Extraordinary General Meeting, to be held on Monday, 11 May 2026, starting at 15:00 CEST. The Extraordinary General Meeting will be held before notary and will take place immediately following the Ordinary General Meeting.
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 April 2026 – 7:00 AM CET Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 31 March 2026. Key Highlights Revenue of €263.4 million, up 10.3% on a reported basis (15.0% at CER 1 ), supported by incremental M&A contribution and outstanding performance in Latin America Organic growth at CER of 3.2%, reflecting positive contributions from all regions Positive momentum in the roll out of our Brands strategy while operational excellence initiatives continue to deliver benefits Completed the Pharmavit acquisition in the Netherlands, with integration of all recently closed transactions progressing as planned FY 2026 guidance: mid- to high-single digit organic sales growth at CER and a REBITDA margin of c.
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 104,200 new shares have been issued on 31 March 2026. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 507,462,601.84.